EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 51 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Grandma Who Sent Accidental Text To Stranger Spends 6th Thanksgiving With... December 1, 2021 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 New Way to Classify Meningioma Brain Tumors Suggests Potential Treatments June 17, 2022 Why Cancer Survivors Should Have a Written Survivorship Care Plan March 9, 2021 Load more HOT NEWS Breast-Cancer Mom Is Living On 84 Pence As She Fights For... A toolkit to address disparities in digitally enabled oncology trials Today is Giving Tuesday Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical...
